Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis[J]. Lancet , 2014,384(9961):2235-2243.
[2]
Kotecha D, Manzano L, Krum H, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient-data meta-analysis[J]. BMJ, 2016, 353: 1855.
[3]
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace,2016,18(11):1609-1678.
[4]
Flora S, Ponikowski P. The sympathetic/ parasympathetic imbalance in heart failure with reduced ejection fraction[J]. Eur Heart J, 2015, 36(30):1974-1982.
[5]
Cohn J N, Pfeffer M A, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) [J]. Eur J Heart Fail, 2003,25(5):659-667.
[6]
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study[J]. Lancet, 2010, 376(9744):875-885.
[7]
Li S J, Sartipy U, Lund L H, et al. Prognostic significance of resting heart rate and use of β blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry[J]. Circ Heart Fail, 2015, 8(5):871-879.
[8]
Mareev Y, Cleland J. Should β -blockers be used in patients with heart failure and atrial fibrillation? [J]. Clin Ther,2015,37(10):2215-2224.
[9]
Kotecha D, Piccini J. Atrial fibrillation in heart failure: what should we do? [J]. Eur Heart J, 2015, 36(46):3250-3257.
2018, Vol. 29 
